Translating Evidence Into Action: Nonsteroidal MRAs in Patients With HF
About this episode
A panel discussion on the role of nonsteroidal MRAs in heart failure management, featuring expert insights and clinical recommendations.
CME credits: 0.25 Valid until: 23-06-2027 Claim your CME credit at https://reachmd.com/programs/cme/translating-evidence-into-action-nonsteroidal-mras-in-patients-with-hf/49259/ In this panel discussion from the ESC Heart Failure Congress 2026, Drs. Muthu Vaduganathan, Michael Böhm, and Koichiro Kinugawa discuss the role of nonsteroidal MRAs in patients with HFmrEF and HFpEF. Using a clinical case, the faculty review evolving recommendations supporting finerenone as part of guideline-directed medical therapy, along with evidence from FINEARTS-HF and related analyses. The discussion highlights considerations for early initiation, use in combination with SGLT2 inhibitors, patient selection, dosing and monitoring, and management of potassium and renal function changes in clinical practice. =
People in this episode
Guests: Muthu Vaduganathan, Michael Böhm, Koichiro Kinugawa
Mentioned in this episode
Organizations: ESC Heart Failure Congress
Products: finerenone, SGLT2 inhibitors
More episodes of ReachMD CME
- No Patient With CKD Left Behind: New Horizons in Patients With CKD Regardless of Diabetes Status
- Closing the Gaps: Global Implementation of Lipid Guidelines
- Unblocking Clinical Inertia: The CMI Era in oHCM Care
- Chairperson’s Perspective: Reframing First-Line and Subsequent Care in Advanced Urothelial Carcinoma – Clinical Implications of the Updated NCCN Guidelines
- Chairperson’s Perspective: HER2 in Solid Tumors – From Pathology to Personalized Treatment Plans
- Before the Scalpel: Identifying Candidates for Perioperative Immunotherapy
Explore listener stats, chart rankings, contacts and more on the ReachMD CME podcast page.